Insiders · CING

Matthew Brams

EVP and Chief Medical Officer at Cingulate Inc. (CING)

Matthew Brams has filed 15 insider reports with the SEC since December 2021, as EVP and Chief Medical Officer at Cingulate Inc. (CING). In the last 12 months Matthew Brams bought $9,808 of stock on the open market. The latest filing, on July 20, 2026, reports grant or award at Cingulate Inc. (CING).

Filings
15
Companies
1
Bought on market
$9,808
Sold on market
None

Companies where Matthew Brams is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Cingulate Inc. logo
CING
Cingulate Inc.
EVP and Chief Medical Officer8,157$9,808$5.04$3.75-26%Jul 20, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Compare Matthew Brams with

Other insiders at the same companies

Questions about Matthew Brams

What is Matthew Brams's role at Cingulate Inc.?
Matthew Brams reports to the SEC as EVP and Chief Medical Officer at Cingulate Inc. (CING), according to the latest filing on July 20, 2026.
How many shares does Matthew Brams own?
After the latest filing that states it, Matthew Brams directly owned 8,157 shares of Cingulate Inc. (CING). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Matthew Brams bought or sold stock recently?
The most recent open-market purchase was on February 6, 2026: bought 1,946 shares of Cingulate Inc. (CING) for $9,808 at an average of $5.04.
How do I get alerts when Matthew Brams files?
Follow Matthew Brams on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Matthew Brams (SEC CIK 0001884361). Totals count each trade once, skipping amendments whose original is on file, from Dec 9, 2021 on. View on SEC EDGAR